ArticleCA: a cancer journal for clinicians
Cancer treatment and survivorship statistics, 2025.
Article in CA: a cancer journal for clinicians. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 277 papers, 12 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
277 citing papers in PubMed, 12 syntheses or guidelines pooled it.
- Cardiovascular risk-prediction models in cancer survivors: a meta-analysis.European heart journal · 2026Pooled it
- How prevalent is fear of cancer recurrence beyond 5 years: a systematic review of validated assessments across tumour types.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Pooled it
- Synthesis of clinical practice guidelines and recommendations for breast cancer survivorship care: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Pooled it
- Health-related quality of life domains relevant to people in Europe undergoing cancer treatment: a systematic review of qualitative research.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026Pooled it
- Exosomal Non-Coding RNAs in Gastrointestinal Cancer Drug Resistance: A Systematic Review of Emerging Mechanisms and Clinical Implications.Journal of cellular and molecular medicine · 2026Pooled it
- Comparative efficacy of different exercise interventions for cancer-related fatigue, health-related quality of life, anxiety and depression symptoms in cancer survivors: a systematic review and network meta-analysis.BMC public health · 2026Pooled it
- A systematic review of financial toxicity measurement instruments for cancer patients based on the COSMIN guideline.Journal of patient-reported outcomes · 2026Pooled it
- Diet, nutrition, and hormone therapy for prostate cancer: a systematic review with implications for future interventions.JNCI cancer spectrum · 2026Pooled it
- Sacituzumab govitecan in metastatic breast cancer: a systematic review and meta-analysis of its clinical benefit and safety.Frontiers in medicine · 2026Pooled it
- The impact of comorbid type 2 diabetes on survival outcomes in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis focusing on lung cancer.Frontiers in endocrinology · 2026Pooled it
- From economic burden to patient-centered solutions: the evolving landscape of financial toxicity in oncology.Frontiers in public health · 2026Pooled it
- Multi-database bibliometric analysis and cross-database comparison of NOSES research in colorectal cancer: integrated evidence from WoSCC and PubMed.Frontiers in oncology · 2026Pooled it
- Understanding the Effects of Cancer-Related Factors on the Association Between Physical Activity and Quality of Life in Breast Cancer Survivors.Journal of physical activity & health · 2026Trial
- The Impact of a Physical Activity Intervention on Cognitive and Mental Health Outcomes in Cancer Survivors.Psycho-oncology · 2026Trial
- Worse Function and Symptoms Among the Most Rural Patients With Advanced Cancer: A Cross-Sectional Analysis.Cancer medicine · 2026Trial
- Results of the AiM, PLan, and act on LIFestYles (AMPLIFY) Weight Loss Intervention Among Survivors of Obesity-Related Cancers: A Randomized Clinical Trial.Journal of the National Comprehensive Cancer Network : JNCCN · 2026Trial
- Website Use and Associations With Behavior Change and Weight Loss in Cancer Survivors and Their Partners: Secondary Analysis of a Randomized Controlled Trial.Journal of medical Internet research · 2026Trial
- Impact of a Reproductive Health Survivorship Care Plan on Fertility, Pregnancy Concerns, and Accessing Reproductive Healthcare Among Young Nulliparous Breast Cancer Survivors.Cancer reports (Hoboken, N.J.) · 2026Trial
- Photodynamic antimicrobial and antineoplastic therapy in veterinary medicine: current status, challenges, and perspectives.The veterinary quarterly · 2026Review
- Association of basal metabolic rate with mortality among cancer survivors: a cohort study emphasizing heterogeneity by gender and age.Annals of medicine · 2026Article
217 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The number of people living with a history of cancer in the United States continues to rise because of the growth and aging of the population as well as improved survival through advances in early detection and treatment. To assist the public health community serve the needs of these survivors, the American Cancer Society and the National Cancer Institute collaborate triennially to estimate cancer prevalence in the United States using data from the Surveillance, Epidemiology, and End Results cancer registries, the Centers for Disease Control and Prevention's National Center for Health Statistics, and the United States Census Bureau. In addition, cancer treatment patterns are presented from the National Cancer Database along with a brief overview of treatment-related side effects. As of January 1, 2025, about 18.6 million people were living in the United States with a history of cancer, and this number is projected to exceed 22 million by 2035. The three most prevalent cancers are prostate (3,552,460), melanoma of the skin (816,580), and colorectum (729,550) among males and breast (4,305,570), uterine corpus (945,540), and thyroid (859,890) among females. About one half (51%) of survivors were diagnosed within the past 10 years, and nearly four fifths (79%) were aged 60 years and older. Racial differences in treatment in 2021 were common across disease stage; for example, Black people with stage I-II lung cancer were less likely to undergo surgery than their White counterparts (47% vs. 52%). Larger disparities exist for rectal cancer, for which 39% of Black people with stage I disease undergo proctectomy or proctocolectomy compared to 64% of their White counterparts. Targeted, multi-level efforts to expand access to high-quality care and survivorship resources are vital to reducing disparities and advancing support for all survivors of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.